Sanjivani Paranteral Ltd — Important, 14-05-2026: Company Update

Sanjivani Paranteral Limited shared its investor presentation for the fourth quarter and full financial year ended March 2026. For Q4 FY26, standalone revenue was INR 10.51 Cr, marking a 42.2% year-on-year decline, with PAT at INR 0.94 Cr, down 57.2%. Full-year standalone revenue stood at INR 64.76 Cr, a 7.6% drop, and PAT was INR 6.92 Cr, down 14.6%. The pharmaceutical company, specializing in injectables and oral solids with significant exports, aims to grow by expanding its product portfolio, venturing into new geographies, and pursuing strategic partnerships and therapeutic diversification.